Establishing a precise consensus price target for Eledon Pharmaceuticals (ELDN) stretching out to the year 2030 is difficult because Wall Street equity research analysts restrict formal target horizons to a 12-month window. Long-term projections found on algorithmic platforms vary wildly and are speculative. A company's stock value by 2030 will depend heavily on clinical trial milestones, regulatory approvals for its lead drug candidates, and long-term commercialization execution rather than fixed multi-year price guesses.